Gilead Sciences Pharmaceuticals Co.
Gilead Sciences Pharmaceuticals Co. (吉利德（上海）医药科技有限公司) is the China regional subsidiary of NASDAQ-listed Gilead Sciences, Inc., commercializing innovative therapeutics for HIV, viral hepatitis, inflammatory diseases, and oncology to Chinese patients through hospitals, physicians, and specialty pharmacy channels.
- Company typePrivate
- Founded1987
- HeadquartersShanghai, China
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Gilead Sciences Pharmaceuticals Co. firmographics
Firmographics- Name
- Gilead Sciences Pharmaceuticals Co.
- Legal name
- 吉利德（上海）医药科技有限公司
- Website
- https://gileadchina.com
- Company type
- Private
- Founded year
- 1987
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Gilead Sciences Pharmaceuticals Co. (吉利德（上海）医药科技有限公司) is the China regional subsidiary of NASDAQ-listed Gilead Sciences, Inc., commercializing innovative therapeutics for HIV, viral hepatitis, inflammatory diseases, and oncology to Chinese patients through hospitals, physicians, and specialty pharmacy channels.
- Ownership category
- akta.pro rank
Gilead Sciences Pharmaceuticals Co. industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Gilead Sciences Pharmaceuticals Co. is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
Gilead Sciences Pharmaceuticals Co. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Pharmaceutical drug sales: Gilead generates revenue through the sale of prescription pharmaceutical products, developing and commercializing innovative medicines for patients with serious diseases.
Distribution channels2 records
Marketing channels2 records
Gilead Sciences Pharmaceuticals Co. product offering
Product offeringCore offering
Gilead Sciences Pharmaceuticals Co. (吉利德（上海）医药科技有限公司) is a biopharmaceutical company that develops, manufactures, and commercializes innovative prescription medicines for serious and life-threatening diseases. Its therapeutic focus centers on virology (HIV/AIDS and viral hepatitis) and oncology, with the company investing in world-class scientific research and simplified treatment regimens to expand patient access in China. The entity operates as the Chinese regional subsidiary of Gilead Sciences, Inc.
Differentiator
Problem solved
Functional benefit
Companies that use Gilead Sciences Pharmaceuticals Co.
Customer profileSegments1 record
Ideal customer profiles1 record
Gilead Sciences Pharmaceuticals Co. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Gilead Sciences Pharmaceuticals Co. partnerships and signals
Strategic signalScale indicators1 record
Gilead Sciences Pharmaceuticals Co. competitors and assessment
Company assessmentBroad incumbents
- Johnson & Johnson Innovative Medicine (China): J&J China operates a large innovative medicine subsidiary with HIV, oncology, and immunology franchises. It is comparable as a multinational pharma China entity with overlapping therapeutic categories, particularly HIV where J&J has historic market presence.
- Novartis (China): Novartis China operates a specialty-focused multinational pharma subsidiary with major oncology and infectious disease franchises. It is comparable as a multinational parent's China entity with overlapping therapeutic emphasis and similar NRDL/pricing exposure.
- AstraZeneca (China): AstraZeneca China is one of the largest multinational pharma subsidiaries by China revenue, with a broad oncology and specialty pipeline. It is comparable as a multinational pharma's China commercial vehicle with significant NRDL exposure and specialty drug focus.
- Roche (China): Roche China is a leading multinational oncology and specialty pharma subsidiary. It is comparable as a U.S./European-headquartered parent's China entity with major emphasis on oncology therapeutics and similar specialty distribution infrastructure.
- Pfizer (China): Pfizer China is one of the largest multinational pharma operations in China across multiple therapeutic areas including oncology and infectious diseases. It is comparable as a broader incumbent multinational subsidiary with overlapping focus areas but a much wider portfolio.
Emerging players
- BeiGene: BeiGene is a China-headquartered oncology biotech with growing global presence, competing with multinational pharma in hematology and solid tumor oncology. It is comparable as a competitor in the China oncology space, particularly relevant given domestic Chinese player dynamics affecting Gilead's subsidiary.
Direct peers
- Bristol-Myers Squibb (China): Bristol-Myers Squibb operates a major China subsidiary focused on oncology, hematology, and immunology. It is directly comparable as a multinational biopharmaceutical subsidiary with a similar therapeutic mix (oncology and specialty) and similar commercial infrastructure in China.
- AbbVie (China): AbbVie China operates as a specialty-focused multinational subsidiary with strengths in HIV (via its collaboration history) and oncology/hematology. It is comparable given similar therapeutic mix and reliance on parent pipeline for specialty drug launches in China.
- GSK (China): GSK China operates as a multinational subsidiary with a strong HIV franchise (via ViiV Healthcare) and infectious disease pipeline. It is directly comparable as a multinational pharma parent with China presence competing in the same HIV and hepatitis therapeutic categories.
- Merck & Co. (MSD China): MSD China operates one of the largest multinational pharma subsidiaries in China with leadership in oncology (Keytruda) and a growing infectious disease portfolio. It is comparable as a U.S. pharma parent's China entity with overlapping therapeutic emphasis on oncology and specialty therapeutics.
Market position
Customer concentration
Gilead Sciences Pharmaceuticals Co. social profiles
Digital presenceGilead Sciences Pharmaceuticals Co. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gilead Sciences Pharmaceuticals Co. leadership team
Management profileNumber of profiles
Gilead Sciences Pharmaceuticals Co. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gilead Sciences Pharmaceuticals Co. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gilead Sciences Pharmaceuticals Co.
What does Gilead Sciences Pharmaceuticals Co. do?
Gilead Sciences Pharmaceuticals Co. (吉利德（上海）医药科技有限公司) is a biopharmaceutical company that develops, manufactures, and commercializes innovative prescription medicines for serious and life-threatening diseases. Its therapeutic focus centers on virology (HIV/AIDS and viral hepatitis) and oncology, with the company investing in world-class scientific research and simplified treatment regimens to expand patient access in China. The entity operates as the Chinese regional subsidiary of Gilead Sciences, Inc.
Is Gilead Sciences Pharmaceuticals Co. a public or private company?
Gilead Sciences Pharmaceuticals Co. is a private company. It is classified as corporate owned and is currently operating.
When was Gilead Sciences Pharmaceuticals Co. founded?
Gilead Sciences Pharmaceuticals Co. was founded in 1987. It employs 101 to 250 people.
Where is Gilead Sciences Pharmaceuticals Co. based?
Gilead Sciences Pharmaceuticals Co. is headquartered in Shanghai, China, in the Asia region.
How does Gilead Sciences Pharmaceuticals Co. make money?
One revenue line is on record: pharmaceutical drug sales.
Who are Gilead Sciences Pharmaceuticals Co.'s main competitors?
Broad incumbents on record are Johnson & Johnson Innovative Medicine (China), Novartis (China), AstraZeneca (China), Roche (China) and Pfizer (China). BeiGene is listed as an emerging player. Direct peers are Bristol-Myers Squibb (China), AbbVie (China), GSK (China) and Merck & Co. (MSD China).
Does Gilead Sciences Pharmaceuticals Co. have an API?
No public API is recorded for Gilead Sciences Pharmaceuticals Co..
What industry is Gilead Sciences Pharmaceuticals Co. in?
Gilead Sciences Pharmaceuticals Co.'s product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.